← All trials
NCT06229288
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 25, 2024
- Primary completion
- May 25, 2027
- Completion date
- May 25, 2027
- First posted
- Jan 29, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 326
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of NantesLead sponsor
- University of Western BrittanyOfficial
- RocheOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.